Your AI strategy is only as strong as your organisation's ability to sustain and execute it
Most pharmaceutical organisations build a strong AI strategy and then watch it lose momentum in the face of competing priorities, capability gaps, and the sheer operational complexity of implementation. This service exists to prevent that — providing the ongoing strategic guidance, expert advisory, and capability building that turns a sound strategy into sustained commercial results.
Why AI strategies lose momentum — and how to prevent it
Building an AI strategy is one challenge. Sustaining it is another — and in our experience, the harder one.
Across the pharmaceutical organisations we work with, the pattern is consistent. A strategy gets built. Leadership is aligned. The first initiatives launch with genuine momentum. And then, quietly, the pressure of competing priorities, capability gaps, and the operational complexity of implementation begins to erode that momentum. Projects stall. Pilots that should have scaled don’t. The strategy that looked compelling in a board presentation begins to feel like a document rather than a direction.
This service is designed specifically for that moment — and for every moment that follows it.
The specific reasons AI initiatives lose momentum in pharmaceutical organisations
In pharmaceutical organisations specifically, AI momentum breaks down at predictable points. The initial strategy engagement ends and the internal team is left to execute without the ongoing expert support needed to navigate the inevitable obstacles. Capability gaps emerge as the work moves from planning to implementation. Competing organisational priorities pull leadership attention away from AI initiatives that require sustained focus to deliver. And without someone maintaining the strategic coherence of the overall programme, individual workstreams begin optimising locally rather than compounding value across the organisation.
Each of these is a solvable problem. Solving them is what this service is designed to do.
What ongoing strategic support makes possible that a one-time strategy engagement cannot
A one-time strategy engagement — however rigorous — produces a blueprint. What it cannot produce is the sustained organisational capability to execute that blueprint as the environment changes, as new AI capabilities emerge, as implementation encounters the inevitable obstacles, and as the board continues to raise its expectations.
The organisations that build durable AI advantage are not those that commission the best strategy document. They are those that maintain the quality of strategic thinking continuously — adapting, course-correcting, and compounding value over time. That requires ongoing expert support, not a single engagement.
The specific point where most pharmaceutical AI programmes begin to unravel
The breaking point is almost always the same. The strategy is built. The first initiatives are scoped. The organisation moves into execution mode. And it is precisely at that transition — from strategy to sustained implementation — that the absence of ongoing expert support becomes critical.
Implementation surfaces obstacles that strategic planning cannot fully anticipate. New AI capabilities emerge that the original blueprint did not account for. Internal stakeholders who were aligned at the strategy stage begin to diverge as the work becomes operationally complex. And the people responsible for driving the programme are also responsible for everything else — which means AI, however strategic, competes with the urgent.
Without ongoing support at that moment, even the strongest strategies quietly stall.
What the Eularis sustained ongoing AI support delivers
The Eularis ongoing AI support operates as a sustained strategic partnership — providing the expert guidance, course-correction, and capability development that the period between strategy and measurable results actually requires.
It begins where the AI Strategic Blueprint ends. The strategy is in place. The priorities are identified. The financial models are built. What comes next — turning that strategy into operational reality inside a complex pharmaceutical organisation — is where most programmes need the most support, and where most programmes are most likely to lose momentum without it.
This service ensures they do not.
How the engagement works
Every engagement begins with a clear strategic foundation — either the Eularis AI Strategic Blueprint if one is not already in place, or a rapid assessment of your existing strategy to identify gaps and priorities.
From there, the ongoing advisory programme provides structured monthly strategic guidance, capability development for your leadership and commercial teams, and hands-on support navigating the specific implementation challenges that arise as your AI programme moves from planning into operation.
The engagement is designed to adapt as your organisation’s needs evolve — scaling the depth of support up or down in response to where you are in the implementation journey, what obstacles you are encountering, and what the board is asking for.
Ready to discuss what ongoing strategic support looks like for your organisation?
A 45-minute AI Strategy Diagnostic is the most direct way to determine whether this service is right for your organisation's current situation — and what a structured engagement would look like in practice. No obligation. No sales process. A direct conversation with a team that has delivered ongoing pharmaceutical AI advisory for over two decades.
Pharmaceutical organisations that have trusted Eularis with their AI strategy
Three levels of ongoing engagement — structured around where your organisation is in its AI journey
The specific commercial challenges this service is designed to address
For Biopharma
For biopharmaceutical organisations, this service addresses the AI challenges that most directly determine commercial performance:
- Connecting AI strategy directly to exclusivity loss timelines — protecting and replacing revenue before, during, and after patent cliff events
- Maximising drug launch performance — ensuring AI-driven targeting, personalisation, and market access strategy are operating at full effectiveness from day one
- Precision HCP engagement — moving from broad segmentation to individually personalised sales and marketing at scale
- Earlier patient identification — finding diagnosed and undiagnosed patient populations faster and more accurately
- Market access strategy — using AI to strengthen payer evidence, improve account targeting, and accelerate access decisions
- Enterprise productivity — building AI-driven efficiency across medical affairs, regulatory, and commercial operations
- Pipeline and portfolio prioritisation — applying AI to the decisions that determine which assets receive investment and in what sequence
The three engagement levels — Optimise, Accelerate, and Transform — are designed to match the depth of support to the scale of your AI ambition. Each builds on the same strategic foundation. Each provides ongoing access to Eularis expertise. And each is structured to deliver measurable commercial outcomes — not ongoing activity without clear results.
The right level depends on where your organisation is today and where it needs to be. That is a conversation we are always willing to have directly.
What pharmaceutical leaders say about working with Eularis on an ongoing basis:
"Eularis brought a rigorous process that really got to the core of the value of our products and attained real-world results for us.”
"The Board found it compelling — especially that while future-proofing the business we are delivering measurable milestones and results that reshape it at the same time."
Choosing the right level of ongoing support
Each engagement level is designed for a different stage of AI maturity and a different scale of commercial ambition. The table below outlines what each includes:
Features
-
Monthly briefing on the most relevant AI developments
-
AI topic-specific training webinar each month
-
Access to our on-demand training library
-
Monthly half-day online AI training for your team
-
Monthly 90-minute strategic guidance session
-
Ecosystem landscape assessment updates
-
Executive half-day strategic plan review session
-
Ongoing project management or data science support
Optimise
Accelerate
Transform
Not sure which level of engagement is right for your organisation?
Most pharmaceutical leaders find it useful to speak directly before choosing an engagement level. A 45-minute conversation with the Eularis team gives you a clear picture of which package fits your organisation's current situation — and what the first 90 days of engagement would look like in practice.
"The Board found it compelling — especially that while future-proofing the business we are delivering measurable milestones and results that reshape it at the same time."
What makes Eularis the right partner for sustained pharmaceutical AI advisory
Eularis has worked exclusively at the intersection of pharmaceutical strategy and artificial intelligence since 2003. That focus — sustained over more than two decades — produces a depth of commercial, regulatory, and organisational understanding that generalist firms cannot replicate and that firms newer to this space have not yet had time to build.
It is the reason our ongoing advisory engagements consistently deliver what one-time strategy documents cannot: the sustained strategic intelligence to navigate the distance between a compelling AI blueprint and measurable commercial results.
Our ongoing advisory engagements are built around the specific challenges and priorities of each organisation — not a standardised programme applied uniformly regardless of context. The strategic guidance we provide reflects two decades of pattern recognition across pharmaceutical AI engagements: what works, what does not, where implementations typically encounter resistance, and how to navigate that resistance without losing momentum.
That accumulated intelligence is what our clients are accessing when they engage Eularis on an ongoing basis. It is not available anywhere else in the same form.
In practice, what our ongoing advisory clients consistently report:
- AI initiatives that maintain strategic coherence and commercial focus through the full implementation cycle — not just in the planning phase
- Leadership teams with the capability and confidence to make informed AI investment decisions independently
- A sustained competitive position as AI capabilities evolve — rather than a strategy that is current at signing and outdated at implementation
- Board presentations on AI that hold up to scrutiny because the underlying strategy and financial logic are continuously maintained
Every ongoing engagement is personally led by Dr. Andrée Bates
Dr. Andrée Bates founded Eularis in 2003 — at a time when applying artificial intelligence to pharmaceutical commercial strategy was considered by most of the industry to be either premature or peripheral. Over the two decades since, she has personally overseen more than 1,000 pharmaceutical AI engagements across clinical development, medical affairs, market access, and commercial operations in organisations across North America, Europe, Japan, and Asia Pacific.
She has lectured on pharmaceutical AI and healthcare innovation at INSEAD, Henley Business School, Fordham University’s Gabelli School of Business, Northwestern University, and Northeastern University — and her published research on AI strategy in pharma is read by executives across the global industry.
When you engage Eularis for ongoing advisory, you are not assigned to a delivery team. You are working directly with the person who has spent longer than anyone else building the methodology your organisation will be using.
The questions that typically bring pharmaceutical leaders to this conversation
- Do you have an AI strategy in place but genuine uncertainty about whether your organisation has the sustained capability to execute it?
- Have promising AI initiatives lost momentum after the initial strategy phase — absorbed by competing priorities before delivering the results they were designed to produce?
- Is your board expecting a more coherent and commercially grounded AI story than your current programme can deliver?
- Are your AI efforts across commercial, medical, R&D, and market access aligned to the same strategic priorities — or drifting toward local optimisation?
- Are you confident that as AI capabilities evolve rapidly over the next 12 to 18 months, your strategy will adapt fast enough to maintain competitive advantage?
If any of these questions expose uncertainty, the conversation is worth having. A 45-minute AI Strategy Diagnostic with the Eularis team gives you an honest, independent read on where your organisation stands — and a clear recommendation on whether ongoing advisory support is the right next step.